Favorable results presented at Hamburg on Twice Daily Dosing (BID) Viracept, on Monday, 10/13/97
Study presented at the Sixth European Conference on Clinical Aspects and Treatment Of HIV-Infection, 1997.
Nine out of 10 patients, in a small pilot study, achieved a high level of response to twice daily dosing (BID) of Viracept.
Agouron is expecting data from a large study ~200 patients, being conducted in Europe, to be released in early 1998, that will confirm these results.
Viracept was used in combination with with 3TC and d4T. Study was by Dr. Michael Sension from North Broward Hospital in Ft. Lauderdale, Florida.
Patients had mean baseline HIV RNA of 194,814 copies/ml (5.04 log10) and mean baseline CD4 cell count of 377 cells/mm3.
Viracept was administered at 1250 mg BID, as opposed to the current 750 mg TID.
One patient was lost to follow up.
At 16 weeks, 100% of patients (9 out of 9) were at viral loads below levels of detectability (2.5 log10
Although not directly comparable, the results appear to be as good if not better than Crixivan -BID-dosing study.
In the Crixivan BID dosing study (1200 mg) presented at ICAAC in September,
75% of patients, 12 out of 16, achieved viral loads below levels of detection. |
